XML 30 R19.htm IDEA: XBRL DOCUMENT

Note 12 - Stock-based Compensation

9 Months Ended

Sep. 30, 2025

Notes to Financial Statements

Share-Based Payment Arrangement [Text Block]

NOTE 12. STOCK-BASED COMPENSATION

Equity Compensation Plans

In October 2007, the Company adopted the 2007 Omnibus Incentive Plan (the “2007 Plan”) to provide for the grant of equity awards, such as stock options, unrestricted and restricted common stock, stock units, dividend equivalent rights, and stock appreciation rights to employees, directors and outside consultants, as determined by the Board. The 2007 Plan expired on March 15, 2017. Upon expiration, new awards cannot be issued pursuant to the 2007 Plan, but outstanding awards continue to be governed by its terms. Stock options granted under the 2007 Plan expire no later than ten years from the date of grant. All stock options outstanding under the 2007 Plan were fully vested as of December 31, 2024.

In March 2017, the Company adopted the 2017 Omnibus Incentive Plan (the “2017 Plan”), which was approved by stockholders on June 2, 2017, to provide for the grant of equity awards, such as nonqualified stock options (“NQSOs”), incentive stock options (“ISOs”), restricted stock, performance shares, stock appreciation rights (“SARs”), RSUs and other share-based awards to employees, directors, and consultants, as determined by the Board. The 2017 Plan does not affect awards previously granted under the 2007 Plan. Upon adoption, the 2017 Plan allowed for awards of up to 66,243 shares of the Company’s common stock, plus an automatic annual increase in the number of shares authorized for awards on the first day of each of the Company’s fiscal years beginning January 1, 2018 through January 1, 2027 equal to (i) 4% of the number of shares of common stock outstanding on the last day of the immediately preceding fiscal year or (ii) such lesser number of shares of common stock as determined by the Board. As of September 30, 2025, there were 14,332 shares available for future awards under the 2017 Plan. Subsequent to September 30, 2025, on October 16, 2025, stockholders approved an amendment to increase the shares authorized under the 2017 Plan by 1,000,000 shares (see Note 19, “Subsequent Events”).

Under the terms of the 2017 Plan, the exercise price of NQSOs, ISOs and SARs may not be less than 100% of the fair market value of the Company’s common stock on the date of grant and, if ISOs are granted to an owner of more than 10% of the Company’s common stock, then not less than 110% of the fair market value of the Company’s common stock on the date of grant. The term of awards will not be longer than ten years or, in the case of ISOs, no longer than five years with respect to holders of more than 10% of the Company’s common stock. Stock options granted to employees generally vest over four years, while options granted to directors and consultants typically vest over a shorter period, subject to continued service. The Company issues new shares of Company common stock to satisfy exercises of options under the 2007 Plan and the 2017 Plan.

Summary of Outstanding Equity Awards

The following table summarizes information about the Company’s stock options and restricted stock outstanding at December 31, 2024, and activity during the nine months ended September 30, 2025:

(in thousands, except years and per share data)		Awards				Weighted- Average Exercise Price				Weighted- Average Remaining Contractual Life (years)				Aggregate Intrinsic Value
Outstanding at December 31, 2024			7			$	471.64				8.3			$	3
Restricted stock units vested			(5	)			—
Options forfeited/cancelled			(1	)			928.62
Outstanding at September 30, 2025			1				448.84				2.9				—

Vested and expected to vest at September 30, 2025			1				448.84				2.9				—
Vested and exercisable at September 30, 2025			1				2,541.07				2.9				—

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of the Company’s common stock as quoted on the NYSE American as of September 30, 2025 for option awards that have an exercise price that is lower than the market price. There were no stock option awards exercised during the three and nine months ended September 30, 2025 and 2024.

As of September 30, 2025, there was no unrecognized compensation cost related to unvested stock options and restricted stock.

Equity Awards to Employees and Directors

The Company grants options to purchase common stock to its employees and directors at prices equal to or greater than the market value of the stock on the dates the options are granted. The Company has estimated the value of stock option awards as of the date of grant by applying the Black-Scholes option pricing model using the single-option valuation approach. The application of this valuation model involves assumptions that are judgmental and subjective in nature. See Note 2, “Summary of Significant Accounting Policies,” for a description of the accounting policies that the Company applied to value its stock-based awards.

The Company did not grant any stock options or shares of restricted stock to employees or directors to purchase shares of the Company’s common stock during the three and nine months ended September 30, 2025. During the nine months ended September 30, 2024, the Company granted 5,148 shares of restricted stock to employees and directors with no such grant for the three months ended September 30, 2024.

For the three months ended September 30, 2025 and 2024, the Company recognized stock-based compensation expense of $4 thousand and $22 thousand, respectively, for prior option awards to employees and directors. For the nine months ended September 30, 2025 and 2024, the Company recognized stock-based compensation expense of $6 thousand and $137 thousand, respectively, for prior option awards to employees and directors.

Stock-Based Awards to Non-Employees

During the three and nine months ended September 30, 2025 and 2024, the Company did not grant options or restricted stock to non-employees in exchange for advisory and consulting services. The Company recognized stock-based compensation expense of $13 thousand for the nine months ended September 30, 2024 and no stock based compensation expense for the three months ended September 30, 2024, as it relates to non-employees, with no comparable expense for the three and nine months ended September 30, 2025.

Summary of Stock-Based Compensation Expense

A summary of the stock-based compensation expense included in results of continuing operations for the options and restricted stock awards discussed above is as follows (in thousands):

Three Months Ended

September

30,

Nine Months Ended

September 30,

2025

2024

2025

2024

General and administrative

$

-

$

22

$

6

$

137